GlassScriptPhysician profile
Kristine Crouch
NPI 1699490748
$1,367.75
in general payments reported to CMS, 2019-2025
19 companies · $455 in 2025
The $455 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $425 · 2024: $487 · 2025: $455.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,302 · Education: $65.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,301.76 |
| Education | $65.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $215.05 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Astellas Pharma US INC | $183.03 | 2023-2024 | Veozah |
| Abbvie INC. | $167.70 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $134.30 | 2023-2025 | Jardiance |
| Novo Nordisk INC | $126.94 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Novartis Pharmaceuticals Corporation | $81.54 | 2023-2024 | |
| Abbott Laboratories | $75.93 | 2023-2025 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $66.40 | 2023-2024 | Farxiga, Airsupra |
| Idorsia Pharmaceuticals US INC | $61.38 | 2023 | Quviviq |
| Lundbeck LLC | $34.67 | 2023-2024 | Rexulti |
| Amgen INC. | $34.23 | 2025 | Otezla, Repatha |
| Pfizer INC. | $29.95 | 2024-2025 | |
| Exact Sciences Corporation | $28.72 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $27.60 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $24.56 | 2025 | Eliquis |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $22.86 | 2025 | Dexcom G6 Transmitter |
| Halozyme INC | $18.27 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.02 | 2024 | Xifaxan, Trulance |
| Glaxosmithkline, LLC. | $16.60 | 2024 | Trelegy Ellipta, Arexvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristine Crouch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.